151 filings
D
NRSN
NeuroSense Therapeutics Ltd
25 Apr 24
$4.47 mm in options / securities to be acquired, sold $4.47 mm, 1 investor
4:01pm
424B5
NRSN
NeuroSense Therapeutics Ltd
12 Apr 24
Prospectus supplement for primary offering
4:30pm
6-K
NRSN
NeuroSense Therapeutics Ltd
12 Apr 24
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
4:30pm
6-K
NRSN
NeuroSense Therapeutics Ltd
10 Apr 24
Report of Foreign Private Issuer
9:00am
6-K
NRSN
NeuroSense Therapeutics Ltd
9 Apr 24
Report of Foreign Private Issuer
8:32am
EFFECT
mlb2btinqtny441c8
9 Apr 24
Notice of effectiveness
12:15am
EFFECT
so5hhis1b77m429
9 Apr 24
Notice of effectiveness
12:15am
6-K
24gda 79nx0cn
5 Apr 24
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
9:28am
POS AM
5bnw9i
4 Apr 24
Prospectus update (post-effective amendment)
5:10pm
POS AM
3s5 gru3540n
4 Apr 24
Prospectus update (post-effective amendment)
4:37pm
6-K
lxglfz5gwx8252g
22 Feb 24
Report of Foreign Private Issuer
8:25am
6-K
vn4rlplsm0ebs5f i3
7 Feb 24
Report of Foreign Private Issuer
9:38am
6-K
q2eum5ierx01yaoj32qj
9 Jan 24
Report of Foreign Private Issuer
8:49am
6-K
fr4s5
9 Jan 24
Report of Foreign Private Issuer
8:48am
424B3
98cnr
27 Dec 23
Prospectus supplement
5:03pm
6-K
qjw01x4z51jns9n5sog
27 Dec 23
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
5:01pm
6-K
vcrr53
21 Dec 23
Report of Foreign Private Issuer
8:45am
424B3
fmh1bjs0viq1lwtzzatw
14 Dec 23
Prospectus supplement
4:30pm
6-K
bx1u0oldr8s2o2iz8wv
14 Dec 23
Report of Foreign Private Issuer
9:41am